• Login
    View Item 
    •   UMB Digital Archive
    • UMB Open Access Articles
    • UMB Coronavirus Publications
    • View Item
    •   UMB Digital Archive
    • UMB Open Access Articles
    • UMB Coronavirus Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of UMB Digital ArchiveCommunitiesPublication DateAuthorsTitlesSubjectsThis CollectionPublication DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    Statistics

    Display statistics

    Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus fusion

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Author
    Coleman, C.M.
    Sisk, J.M.
    Frieman, M.B.
    Date
    2016
    Journal
    Journal of Virology
    Publisher
    American Society for Microbiology
    Type
    Article
    
    Metadata
    Show full item record
    See at
    https://doi.org/10.1128/JVI.01429-16
    Abstract
    The highly pathogenic severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) cause significant morbidity and morality. There is currently no approved therapeutic for highly pathogenic coronaviruses, even as MERS-CoV is spreading throughout the Middle East. We previously screened a library of FDA-approved drugs for inhibitors of coronavirus replication in which we identified Abelson (Abl) kinase inhibitors, including the anticancer drug imatinib, as inhibitors of both SARS-CoV and MERS-CoV in vitro. Here we show that the anti-CoV activity of imatinib occurs at the early stages of infection, after internalization and endosomal trafficking, by inhibiting fusion of the virions at the endosomal membrane. We specifically identified the imatinib target, Abelson tyrosine-protein kinase 2 (Abl2), as required for efficient SARS-CoV and MERS-CoV replication in vitro. These data demonstrate that specific approved drugs can be characterized in vitro for their anticoronavirus activity and used to identify host proteins required for coronavirus replication. This type of study is an important step in the repurposing of approved drugs for treatment of emerging coronaviruses.
    Sponsors
    This work, including the efforts of Matthew B. Frieman, was funded by HHS|NIH| National Institute of Allergy and Infectious Diseases (NIAID) (AI095569). This work, including the efforts of Judith Miriam White, was funded by HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) (R21AI103601 and R01AI114776). This work, including the efforts of Jeanne M. Sisk, was funded by HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) (AI118303).
    Keyword
    Abelson tyrosine-protein kinase 2
    SARS-CoV
    MERS-CoV
    SARS Virus
    Middle East Respiratory Syndrome Coronavirus
    Coronavirus Infections
    Protein Kinases
    Imatinib Mesylate
    Identifier to cite or link to this item
    https://www.scopus.com/inward/record.uri?eid=2-s2.0-84990252098&doi=10.1128%2fJVI.01429-16&partnerID=40&md5=7ae855957d02226d0817b58ee7da918a; http://hdl.handle.net/10713/12403
    ae974a485f413a2113503eed53cd6c53
    10.1128/JVI.01429-16
    Scopus Count
    Collections
    UMB Coronavirus Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2021)  DuraSpace
    Quick Guide | Policies | Contact Us | UMB Health Sciences & Human Services Library
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.